{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:20:25Z","timestamp":1783592425881,"version":"3.55.0"},"reference-count":15,"publisher":"Bioscientifica","issue":"8","funder":[{"name":"Clinician Scientist Program funded by DFG","award":["FU 356\/12-1"],"award-info":[{"award-number":["FU 356\/12-1"]}]}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The efficacy of lenvatinib in treating gastrointestinal neuroendocrine tumors (GI-NETs) has been explored in preclinical studies and early-phase clinical trials, but real-world data remain limited. Data of sixteen patients (median age 65 years; 62.5% female) with advanced and progressive GI-NET who were treated with lenvatinib at the ENETS Center, University Hospital Essen, between July 2019 and February 2024 were analyzed. Patients received all other approved therapies and showed progression within 2 months. Salvage therapy with lenvatinib was initiated after approval from health insurance. Most NETs originated in the small intestine (94%) with a median Ki-67 index of 3.5%. Before lenvatinib, patients received a median of four lines of treatment (range 3\u20137), including somatostatin analogs (100%), everolimus (100%), chemotherapy (25%) and PRRT (88%). Surgery of the primary and\/or metastatic lesions was performed in 81% and ablative therapies in 38%. The median time between NET diagnosis and the initiation of lenvatinib was 100 months. The overall response rate on salvage therapy was 29% and the clinical benefit rate was 100%. The median progression-free survival (PFS) on lenvatinib was 10 months and the median overall survival (OS) after the initiation of lenvatinib reached 113 months. Hypertension was associated with significantly longer PFS (24.5 months, P = 0.007), whereas weight loss correlated with shorter PFS (4 months, P = 0.0032). In this retrospective single-center case analysis, lenvatinib demonstrated promising results in heavily pre-treated and rapidly progressing GI-NET. With an OS of 9.4 years after start of salvage therapy, these results highlight the value of lenvatinib as a therapeutic option for advanced GI-NET patients with otherwise limited treatment alternatives.<\/jats:p>","DOI":"10.1530\/erc-25-0165","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T13:10:14Z","timestamp":1754053814000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["Lenvatinib as salvage therapy in advanced and progressive GI-NET"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0244-3510","authenticated-orcid":true,"given":"Annie","family":"Mathew","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, and Division of Laboratory Research, Endocrine Tumor Center at WTZ\/Comprehensive Cancer Center and ENETS Center of Excellence, University Hospital Essen, University Duisburg-Essen 1 , ,","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d\u2019Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon 2 , ,","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Unger","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, and Division of Laboratory Research, Endocrine Tumor Center at WTZ\/Comprehensive Cancer Center and ENETS Center of Excellence, University Hospital Essen, University Duisburg-Essen 1 , ,","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Fendler","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Essen, German Cancer Consortium (DKTK), West German Cancer Center 3 , ,","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Theurer","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Essen, University of Duisburg-Essen 4 , ,","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0995-667X","authenticated-orcid":true,"given":"Frank","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, Section of Endocrine Surgery, University Hospital Essen, University Duisburg-Essen 5 , ,","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Fuhrer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, and Division of Laboratory Research, Endocrine Tumor Center at WTZ\/Comprehensive Cancer Center and ENETS Center of Excellence, University Hospital Essen, University Duisburg-Essen 1 , ,","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Lahner","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, and Division of Laboratory Research, Endocrine Tumor Center at WTZ\/Comprehensive Cancer Center and ENETS Center of Excellence, University Hospital Essen, University Duisburg-Essen 1 , ,","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2026070905450125900_bib1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070905450125900_bib2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"2026070905450125900_bib3","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070905450125900_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13343","article-title":"European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kudla","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2026070905450125900_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13306","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1\u2013G3","volume":"35","author":"Panzuto","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2026070905450125900_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13423","article-title":"European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J Neuroendocrinol"},{"key":"2026070905450125900_bib7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"2026070905450125900_bib8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JOP.18.00135","article-title":"Management of small bowel neuroendocrine tumors","volume":"14","author":"Scott","year":"2018","journal-title":"J Oncol Pract"},{"key":"2026070905450125900_bib9","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"2026070905450125900_bib10","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026070905450125900_bib11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00535-021-01785-0","article-title":"Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT","volume":"56","author":"Okusaka","year":"2021","journal-title":"J Gastroenterol"},{"key":"2026070905450125900_bib12","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/cncr.35185","article-title":"Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study","volume":"130","author":"Piscaglia","year":"2024","journal-title":"Cancer"},{"key":"2026070905450125900_bib13","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1038\/s41598-022-10514-3","article-title":"Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan","volume":"12","author":"Fujita","year":"2022","journal-title":"Sci Rep"},{"key":"2026070905450125900_bib14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jgh.15727","article-title":"Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma","volume":"37","author":"Kim","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"2026070905450125900_bib15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/8\/ERC-25-0165.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/8\/ERC-25-0165.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0165\/145232\/erc-25-0165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0165\/145232\/erc-25-0165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:45:08Z","timestamp":1783590308000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/8\/e250165\/25957\/Lenvatinib-as-salvage-therapy-in-advanced-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0165","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"e250165"}}